Human sHER-2 Instant ELISA

Description: The human sHer-2 Instant ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sHer-2. The human sHer 2 Instant ELISA is for research use only. Not for diagnostic or therapeutic procedures.

The human HER-2 gene encodes a putative transmembrane growth factor receptor (p185 protein) that is closely related to the epidermal growth factor receptor protein.

Both HER-2 oncogene amplification and oncoprotein overexpression have been correlated with breast, ovarian, gastric, lung, and other cancers.

In 15-40 % of primary breast cancers, amplification of the HER-2 oncogen is found which is highly correlated with overexpression of the encoded protein and seems to play a major role especially during the initiation of ductal carcinomas. HER-2 overexpression is described as independent prognostic factor with greater predictive power than most of the currently used prognostic tools - especially in axillary lymph-node-positive breast cancer patients.

32 % of ovarian carcinomas overexpress the HER-2 oncoprotein. Survival of those patients is significantly worse compared with cases of normal HER-2 protein expression. Additionally, patients whose tumors have high HER-2 protein expression are significantly less likely to have a complete response to primary therapy. A correlation between HER-2 expression, and clinical outcome has been also demonstrated for head and neck, salivary gland and placental carcinomas.

HER-2 is useful in identifying cancer cells with increased aggressiveness. Soluble p97-115 HER-2 (the soluble circulating fragment of p185 HER-2) protein levels in serum can be used as diagnostic tool for monitoring the extent of tumor spread, postoperative relapse and/or metastatic risk for different cancers.

Citations: Nagy,Peter; Friedlander,Elza; Tanner,Minna; Kapanen,Anita I.; Carraway,Kermit L.; Isola,Jorma; Jovin,Thomas M.. Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line. Cancer Research 2005;65:473-482. (Link)

Tan,W.B.; Jiang,S.; Zhang,Y.. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007;28:1565-1571. (Link)

Tsigris,C.; Karayiannakis,A.J.; Zbar,A.; Syrigos,K.N.; Baibas,N.; Diamantis,T.; Alexiou,D.. Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Letters 2002;184:215-222. (Link)

Perez,E.A.; Geeraerts,L.; Suman,V.J.; Adjei,A.A.; Baron,A.T.; Hatfield,A.K.; Maihle,N.; Michalak,J.C.; Kuross,S.A.; Kugler,J.W.; Lafky,J.M.; Ingle,J.N.. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Annals of Oncology 2002;13:1225-1235. (Link)

Friess,Thomas; Scheuer,Werner; Hasmann,Max. Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy. Clinical Cancer Research 2005;11:5300-5309. (Link)

References: Stenman,G.; Sandros,J.; Nordkvist,A.; Mark,J.; Sahlin,P.. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes.Cancer 1991;3:128-135. (Link)

Paik,S.; Hazan,R.; Fisher,E.R.; Sass,R.E.; Fisher,B.; Redmond,C.; Schlessinger,J.; Lippman,M.E.; King,C.R.. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J.Clin.Oncol. 1990;8:103-112. (Link)

Heatley,M.; Maxwell,P.; Whiteside,C.; Toner,P.G.. C-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Pathol.Res.Pract. 1993;189:261-266. (Link)

Wright,C.; Angus,B.; Nicholson,S.; Sainsbury,J.R.; Cairns,J.; Gullick,W.J.; Kelly,P.; Harris,A.L.; Horne,C.H.. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090. (Link)

Ohguri,T.; Sato,Y.; Koizumi,W.; Saigenji,K.; Kameya,T.. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator?. Int.J.Cancer 1993;53:75-79. (Link)

Kynast,B.; Binder,L.; Marx,D.; Zoll,B.; Schmoll,H.J.; Oellerich,M.; Schauer,A.. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J.Cancer Res.Clin.Oncol. 1993;119:249-252. (Link)

Dittadi,R.; Donisi,P.M.; Brazzale,A.; Marconato,R.; Spina,M.; Gion,M.. Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters. Anticancer Res. 1992;12:2005-2010. (Link)

Seidman,J.D.; Frisman,D.M.; Norris,H.J.. Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasms. Cancer 1992;70:2857-2860. (Link)

Sato,K.; Moriyama,M.; Mori,S.; Saito,M.; Watanuki,T.; Terada,K.; Okuhara,E.; Akiyama,T.; Toyoshima,K.; Yamamoto,T.; .. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493-2498. (Link)

Berchuck,A.; Kamel,A.; Whitaker,R.; Kerns,B.; Olt,G.; Kinney,R.; Soper,J.T.; Dodge,R.; Clarke-Pearson,D.L.; Marks,P.; .. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-4091. (Link)

Ye,D.W.; Zheng,J.F.; Qian,S.X.; Ma,Y.J.. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urol.Res. 1993;21:39-43. (Link)

Tandon,A.K.; Clark,G.M.; Chamness,G.C.; Ullrich,A.; McGuire,W.L.. HER-2/neu oncogene protein and prognosis in breast cancer. J.Clin.Oncol. 1989;7:1120-1128. (Link)

Nakae,S.; Komiyama,Y.; Nambu,A.; Sudo,K.; Iwase,M.; Homma,I.; Sekikawa,K.; Asano,M.; Iwakura,Y.. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17:375-387. (Link)

Kern,J.A.; Schwartz,D.A.; Nordberg,J.E.; Weiner,D.B.; Greene,M.I.; Torney,L.; Robinson,R.A.. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990;50:5184-5187. (Link)

Yu,D.; Wolf,J.K.; Scanlon,M.; Price,J.E.; Hung,M.C.. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993;53:891-898. (Link)

Osaki,A.; Toi,M.; Yamada,H.; Kawami,H.; Kuroi,K.; Toge,T.. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am.J.Surg. 1992;164:323-326. (Link)

Slamon,D.J.; Clark,G.M.; Wong,S.G.; Levin,W.J.; Ullrich,A.; McGuire,W.L.. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Link)

Tsai,C.M.; Chang,K.T.; Perng,R.P.; Mitsudomi,T.; Chen,M.H.; Kadoyama,C.; Gazdar,A.F.. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J.Natl.Cancer Inst. 1993;85:897-901. (Link)

Craven,J.M.; Pavelic,Z.P.; Stambrook,P.J.; Pavelic,L.; Gapany,M.; Kelley,D.J.; Gapany,S.; Gluckman,J.L.. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992;12:2273-2276. (Link)

Slamon,D.J.; Godolphin,W.; Jones,L.A.; Holt,J.A.; Wong,S.G.; Keith,D.E.; Levin,W.J.; Stuart,S.G.; Udove,J.; Ullrich,A.; .. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Link)

al-Kasspooles,M.; Moore,J.H.; Orringer,M.B.; Beer,D.G.. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int.J.Cancer 1993;54:213-219. (Link)

Paterson,M.C.; Dietrich,K.D.; Danyluk,J.; Paterson,A.H.; Lees,A.W.; Jamil,N.; Hanson,J.; Jenkins,H.; Krause,B.E.; McBlain,W.A.; .. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567. (Link)

Rubin,S.C.; Finstad,C.L.; Wong,G.Y.; Almadrones,L.; Plante,M.; Lloyd,K.O.. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am.J.Obstet.Gynecol. 1993;168:162-169. (Link)